ACIU vs RLFTY
AC Immune SA and Relief Therapeutics Holding SA, side by side — 3 fiscal years reported in CHF, drawn from SEC filings.
At a glance
Most recent reported year
| Metric | ACIU | RLFTY |
|---|---|---|
| Revenue | CHF 3.6M | CHF 6.3M |
| Net income | CHF -70.4M | CHF -98.2M |
| Gross margin | — | — |
| Net margin | −1971.6% | −1551.5% |
| Return on equity | — | — |
| Diluted EPS | −CHF 0.70 | −CHF 8.35 |
| Dividend / share | — | — |
| Payout ratio | — | — |
| Free cash flow | CHF -70.2M | CHF -18.1M |
| Equity | — | — |
| Net debt / equity | — | — |
| Current ratio | 1.02× | 2.65× |
| Revenue CAGR 5y | −25.4% | — |
| Profit CAGR 5y | — | — |
RLFTY bills 1.8× the revenue of ACIU, and both closed the last reported year at a loss.
The stronger figure of the pair is set in bold. That is arithmetic, not a recommendation — this page does not pick a winner.
Advertisement
AdSense · Leaderboard 728×90 · responsive
Revenue by year
3 years side by side
| Fiscal year | ACIU | RLFTY |
|---|---|---|
| FY2023 | CHF 14.8M | CHF 6.3M |
| FY2022 | CHF 3.9M | CHF 7.1M |
| FY2021 | CHF 0 | CHF 4.5M |
Net income by year
Bottom line
| Fiscal year | ACIU | RLFTY |
|---|---|---|
| FY2023 | CHF -54.2M | CHF -98.2M |
| FY2022 | CHF -70.8M | CHF -50.8M |
| FY2021 | CHF -73.0M | CHF -34.7M |
Advertisement
AdSense · Rectangle 336×280